Desocort 0.25%20 gm

Desocort 0.25% is a topical corticosteroid indicated for the relief of the inflammatory and pruritic (itchy) manifestations of corticosteroid-responsive dermatoses.

Established/FDA-labeled use

• Relief of inflammation and itching in corticosteroid-responsive skin conditions such as eczema, atopic dermatitis, contact dermatitis, and plaque psoriasis.

Higher-potency indication

Because Desocort 0.25% is a higher-potency topical corticosteroid, it is typically reserved for more resistant or extensive corticosteroid-responsive dermatoses that have not responded adequately to milder topical steroids, used under a physician's guidance.

Desocort 0.25% is not indicated for use on the face, groin, axillae, or other thin-skinned/intertriginous areas without specific medical guidance, and is not intended for long-term continuous use.

Desoximetasone is available (depending on brand/formulation) as a topical cream, ointment, gel, or spray, typically in strengths of 0.05% w/w or 0.25% w/w Desoximetasone as the active ingredient, in a suitable dermatologic base.

Exact strength and formulation should be confirmed on the product label, as different Desoximetasone presentations differ in potency and approved indications.

Desocort 0.25% is a synthetic, non-fluorinated topical corticosteroid used in dermatology for its anti-inflammatory, antipruritic, and vasoconstrictive properties.

Depending on strength and vehicle, Desocort 0.25% is classified as a high to super-high potency (Group I-III) topical corticosteroid, which distinguishes it from milder over-the-counter topical steroids and makes it more suitable for resistant or extensive corticosteroid-responsive dermatoses, under medical supervision.

Topical Corticosteroid (high to super-high potency); Desocort 0.25% belongs to the synthetic glucocorticoid class of dermatologic agents.

Desoximetasone exerts its therapeutic effect by binding to intracellular glucocorticoid receptors in skin cells, inducing anti-inflammatory proteins (e.g., lipocortins) that inhibit phospholipase A2. This reduces the release of arachidonic acid and downstream inflammatory mediators such as prostaglandins and leukotrienes.

The net effects of Desoximetasone include suppression of local inflammation, reduced capillary permeability and dilation (vasoconstriction), inhibition of leukocyte migration to the site of inflammation, and reduction of pruritus (itching).

Systemic absorption of Desoximetasone through intact skin is normally low but increases with higher potency formulations, application to thin or damaged skin, use of occlusive dressings, larger treated surface area, and prolonged use, which can lead to measurable systemic corticosteroid effects.

Desocort 0.25% is for external (topical) use on the skin only. To apply:

• Wash and dry hands before and after application (unless treating the hands).
• Apply a thin film of Desocort 0.25% and gently rub it into the affected area only.
• Avoid contact with eyes, mouth, and mucous membranes; Desocort 0.25% is not for ophthalmic, oral, or intravaginal use.
• Do not cover the treated area with an occlusive (airtight) dressing unless a physician specifically directs it.
• Wash hands thoroughly after each application unless the hands are the treated area.

Because Desocort 0.25% is applied topically, clinically significant drug interactions are uncommon with normal use. However:

• Other topical products: Avoid applying other topical medications, cosmetics, or irritants to the same skin area as Desocort 0.25% unless approved by a physician, as this may alter absorption or irritation risk.
• Strong CYP3A4 inhibitors (e.g., ritonavir, itraconazole, ketoconazole): With extensive body-surface application, prolonged use, or use under occlusion, systemic absorption of Desocort 0.25% may be increased, raising the theoretical risk of systemic corticosteroid effects; such combinations warrant caution.
• Other systemic or topical corticosteroids: Concurrent use may increase the cumulative risk of HPA-axis suppression and should be avoided unless directed by a physician.

Most adverse effects of Desocort 0.25% are local and occur at or near the application site.

Common local effects

• Burning, stinging, or itching at the application site
• Dryness or irritation of the skin
• Folliculitis and acneiform eruptions

Less common, with prolonged/occlusive/extensive use

• Skin atrophy, striae (stretch marks), and telangiectasia (visible small blood vessels)
• Hypopigmentation of treated skin
• Perioral dermatitis and allergic contact dermatitis
• Secondary skin infection

Systemic effects (uncommon, generally with extensive/prolonged/occluded use)

Reversible hypothalamic-pituitary-adrenal (HPA)-axis suppression and Cushingoid features (see Precautions and Warnings).

Pregnancy: Desocort 0.25% has shown teratogenic effects in animal studies at systemic exposures several times higher than typical human topical exposure. Desocort 0.25% should be used during pregnancy only if clearly needed, applied to the smallest area for the shortest duration, and only after the potential benefit has been weighed against potential risk to the fetus, in consultation with a physician.

Lactation: It is not known whether topical Desocort 0.25% is excreted in human breast milk in clinically significant amounts. As a precaution, breastfeeding mothers should avoid applying Desocort 0.25% directly to the breast/nipple area and should consult a physician before use while breastfeeding.

HPA-axis suppression: Desocort 0.25% can be absorbed through the skin in sufficient amounts to produce reversible hypothalamic-pituitary-adrenal (HPA)-axis suppression and, rarely, manifestations of Cushing's syndrome. Risk is higher with higher-potency formulations, larger treated surface area, prolonged use, use under occlusion, application to damaged/thin skin, and in patients with hepatic impairment. Use the lowest effective potency and shortest duration necessary.

Local skin changes: Prolonged use, especially on thin-skinned areas (face, groin, axillae, skin folds) or under occlusion, increases the risk of skin atrophy, striae, and telangiectasia (see Side Effects). Avoid these areas without specific medical guidance.

Not for long-term continuous use: Desocort 0.25% is not intended for uninterrupted long-term therapy. Treatment should be reassessed periodically by a physician, and therapy limited to the lowest effective duration.

Infection: Discontinue Desocort 0.25% and seek medical evaluation if the treated condition worsens or shows signs of secondary infection.

Not for ophthalmic, oral, or intravaginal use. Avoid contact with eyes.

Pediatric caution: Avoid use in children without specific pediatric dosing/duration guidance, given the increased risk of systemic absorption relative to body surface area in this population (see Use in Special Populations).

Topical overdose (excessive amount, frequency, duration, or use under occlusion) of Desocort 0.25% can lead to systemic corticosteroid effects, including HPA-axis suppression and, rarely, Cushingoid features.

If accidental ingestion of Desocort 0.25% occurs, or if signs of systemic corticosteroid toxicity develop, seek immediate medical attention or contact a poison control center/emergency services rather than attempting home treatment.

Store at room temperature (below 30°C), away from light and moisture. Keep the container tightly closed. Spray/aerosol formulations are flammable - keep away from heat, open flame, and do not puncture or incinerate the container. Keep out of reach of children.

Pediatric patients: Children have a larger skin-surface-to-body-weight ratio than adults, increasing their risk of HPA-axis suppression and Cushingoid effects with topical corticosteroids such as Desocort 0.25%. Use in children should be limited to the lowest effective potency/duration and only under specific physician guidance (see Pediatric Uses).

Elderly patients: No specific dose adjustment is established, but elderly patients often have thinner, more fragile skin and may be at higher risk of local skin atrophy with prolonged Desocort 0.25% use; use the lowest effective duration.

Hepatic impairment: Hepatic failure is a recognized risk factor for increased systemic absorption and HPA-axis suppression with topical corticosteroids; use Desocort 0.25% with caution and monitor accordingly.

Renal impairment: No specific dose adjustment is established for topical Desocort 0.25%, as systemic exposure is normally minimal with recommended use.

Desocort 0.25% is generally recommended for short-term, intermittent use. Depending on formulation, use is typically limited to a maximum of about 2 to 4 weeks of continuous therapy. If no improvement is seen within 2 weeks, or if the condition worsens, treatment should be reassessed by a physician. Desocort 0.25% is not intended for uninterrupted long-term/continuous therapy without periodic medical reassessment.

Desoximetasone belongs to the topical corticosteroid (synthetic glucocorticoid) drug class, specifically the high to super-high potency (Group I-III) tier of topical steroids.

Desoximetasone binds to glucocorticoid receptors in the cytoplasm of skin cells. The activated receptor-drug complex translocates to the nucleus and modulates gene transcription, inducing synthesis of anti-inflammatory mediators (e.g., lipocortin-1) that inhibit phospholipase A2, thereby reducing production of arachidonic acid and its inflammatory derivatives (prostaglandins, leukotrienes).

This produces the anti-inflammatory, antipruritic, and vasoconstrictive actions that underlie the clinical effect of Desoximetasone in corticosteroid-responsive dermatoses.

Category C

The safety and effectiveness of Desocort 0.25% in pediatric patients below the age evaluated for each specific formulation have not been established. Where pediatric use is described on the product label (varying by formulation - cream, ointment, gel, or spray), it is generally restricted to older children/adolescents and short durations.

Because children have a greater skin-surface-area-to-body-weight ratio than adults, they absorb proportionally more topical corticosteroid and are at increased risk of HPA-axis suppression, Cushing's syndrome, and growth suppression with Desocort 0.25%. Desocort 0.25% should be avoided in children without specific pediatric dosing and duration guidance from a physician, and used only on the smallest area for the shortest possible time when prescribed.